Compare Aurobindo Pharma with FDC LTD. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs FDC LTD. - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA FDC LTD. AUROBINDO PHARMA/
FDC LTD.
 
P/E (TTM) x 14.0 17.1 81.6% View Chart
P/BV x 3.0 2.3 130.9% View Chart
Dividend Yield % 0.4 0.0 -  

Financials

 AUROBINDO PHARMA   FDC LTD.
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-18
FDC LTD.
Mar-18
AUROBINDO PHARMA/
FDC LTD.
5-Yr Chart
Click to enlarge
High Rs809319 253.6%   
Low Rs504164 307.3%   
Sales per share (Unadj.) Rs281.161.6 455.9%  
Earnings per share (Unadj.) Rs41.49.9 415.7%  
Cash flow per share (Unadj.) Rs50.912.0 425.3%  
Dividends per share (Unadj.) Rs2.500-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs199.473.2 272.5%  
Shares outstanding (eoy) m585.88174.40 335.9%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x2.33.9 59.6%   
Avg P/E ratio x15.924.3 65.4%  
P/CF ratio (eoy) x12.920.2 63.9%  
Price / Book Value ratio x3.33.3 99.8%  
Dividend payout %6.00-   
Avg Mkt Cap Rs m384,63042,118 913.2%   
No. of employees `00017.35.5 313.4%   
Total wages/salary Rs m21,3082,167 983.4%   
Avg. sales/employee Rs Th9,500.71,943.7 488.8%   
Avg. wages/employee Rs Th1,229.4391.7 313.8%   
Avg. net profit/employee Rs Th1,397.9313.7 445.6%   
INCOME DATA
Net Sales Rs m164,66610,751 1,531.7%  
Other income Rs m1,020510 200.1%   
Total revenues Rs m165,68611,260 1,471.4%   
Gross profit Rs m37,7182,267 1,663.8%  
Depreciation Rs m5,580351 1,587.8%   
Interest Rs m77714 5,551.4%   
Profit before tax Rs m32,3802,411 1,343.0%   
Minority Interest Rs m31-5 -654.2%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m8,183671 1,219.1%   
Profit after tax Rs m24,2291,735 1,396.4%  
Gross profit margin %22.921.1 108.6%  
Effective tax rate %25.327.8 90.8%   
Net profit margin %14.716.1 91.2%  
BALANCE SHEET DATA
Current assets Rs m121,8787,213 1,689.8%   
Current liabilities Rs m86,8062,104 4,126.4%   
Net working cap to sales %21.347.5 44.8%  
Current ratio x1.43.4 41.0%  
Inventory Days Days13054 238.3%  
Debtors Days Days6828 246.6%  
Net fixed assets Rs m81,0376,865 1,180.5%   
Share capital Rs m586175 334.4%   
"Free" reserves Rs m116,21812,586 923.4%   
Net worth Rs m116,80412,761 915.3%   
Long term debt Rs m4,5126 75,200.0%   
Total assets Rs m211,05215,041 1,403.1%  
Interest coverage x42.7173.2 24.6%   
Debt to equity ratio x00 8,215.8%  
Sales to assets ratio x0.80.7 109.2%   
Return on assets %11.811.6 101.9%  
Return on equity %20.713.6 152.6%  
Return on capital %27.419.0 144.3%  
Exports to sales %012.3 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA1,327 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m80,7271,889 4,273.9%   
Fx outflow Rs m34,7000-   
Net fx Rs m46,0271,889 2,436.8%   
CASH FLOW
From Operations Rs m19,5481,498 1,304.6%  
From Investments Rs m-19,570201 -9,731.2%  
From Financial Activity Rs m8,642-1,694 -510.0%  
Net Cashflow Rs m8,92210 86,622.3%  

Share Holding

Indian Promoters % 54.1 68.9 78.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 4.7 169.1%  
FIIs % 27.7 7.5 369.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 19.0 53.7%  
Shareholders   69,601 23,730 293.3%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   SUVEN LIFESCIENCES  SHASUN PHARMA  PFIZER  TTK HEALTHCARE  ORCHID PHARMA LTD  

Compare AUROBINDO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps 470 Points; Energy and Banking Stocks Witness Selling(Closing)

Indian share markets witnessed negative trading activity throughout the day and ended deep in the red. The BSE Sensex fell over 550 points intraday and breached the 36,000 mark.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

FDC LTD. Announces Quarterly Results (1QFY20); Net Profit Up 2.4% (Quarterly Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

For the quarter ended June 2019, FDC LTD. has posted a net profit of Rs 523 m (up 2.4% YoY). Sales on the other hand came in at Rs 3 bn (up 17.9% YoY). Read on for a complete analysis of FDC LTD.'s quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

FDC LTD. Announces Quarterly Results (4QFY19); Net Profit Up 6.8% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, FDC LTD. has posted a net profit of Rs 337 m (up 6.8% YoY). Sales on the other hand came in at Rs 3 bn (down 0.6% YoY). Read on for a complete analysis of FDC LTD.'s quarterly results.

FDC LTD. 2017-18 Annual Report Analysis (Annual Result Update)

Mar 28, 2019 | Updated on Mar 28, 2019

Here's an analysis of the annual report of FDC LTD. for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of FDC LTD.. Also includes updates on the valuation of FDC LTD..

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Sep 19, 2019 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 5-YR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS